- Home
- IMCR vs VET Comparison
IMCR vs VET Comparison
Compare IMCR & VET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- VET
- Stock Information
- Founded
- IMCR 2008
- VET 1994
- Country
- IMCR United Kingdom
- VET Canada
- Employees
- IMCR N/A
- VET N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- VET Oil & Gas Production
- Sector
- IMCR Health Care
- VET Energy
- Exchange
- IMCR Nasdaq
- VET Nasdaq
- Market Cap
- IMCR 1.4B
- VET N/A
- IPO Year
- IMCR 2021
- VET N/A
- Fundamental
- Price
- IMCR $28.90
- VET $8.03
- Analyst Decision
- IMCR Buy
- VET
- Analyst Count
- IMCR 12
- VET 0
- Target Price
- IMCR $63.00
- VET N/A
- AVG Volume (30 Days)
- IMCR 372.8K
- VET 1.4M
- Earning Date
- IMCR 05-07-2025
- VET 03-05-2025
- Dividend Yield
- IMCR N/A
- VET 4.30%
- EPS Growth
- IMCR N/A
- VET N/A
- EPS
- IMCR N/A
- VET N/A
- Revenue
- IMCR $310,202,000.00
- VET $1,253,410,386.00
- Revenue This Year
- IMCR $18.97
- VET $29.31
- Revenue Next Year
- IMCR $8.43
- VET $2.74
- P/E Ratio
- IMCR N/A
- VET N/A
- Revenue Growth
- IMCR 24.36
- VET N/A
- 52 Week Low
- IMCR $27.19
- VET $7.09
- 52 Week High
- IMCR $66.00
- VET $12.79
- Technical
- Relative Strength Index (RSI)
- IMCR 49.95
- VET 44.40
- Support Level
- IMCR $28.92
- VET $7.43
- Resistance Level
- IMCR $30.04
- VET $8.48
- Average True Range (ATR)
- IMCR 1.49
- VET 0.24
- MACD
- IMCR 0.10
- VET 0.08
- Stochastic Oscillator
- IMCR 53.71
- VET 56.67
Stock Price Comparison Chart: IMCR vs VET
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.